Find clinical trials for Acute Myeloid Leukemia (AML) in San Francisco, CA
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near San Francisco, CA, USA:
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
San Francisco, California, United States and 125 other locations
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Palo Alto, California, United States and 33 other locations
the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML....
Phase 1
Palo Alto, California, United States and 8 other locations
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differen...
Phase 1
San Francisco, California, United States and 13 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
San Francisco, California, United States and 27 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
San Francisco, California, United States and 73 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Oakland, California, United States and 43 other locations
in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...
Phase 1, Phase 2
Palo Alto, California, United States and 33 other locations
cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Vene...
Phase 2
Palo Alto, California, United States and 8 other locations
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human ...
Phase 1, Phase 2
Stanford, California, United States and 13 other locations
Clinical trials
Research sites
Resources
Legal